Clinical Trials Logo

Epilepsy, Complex Partial clinical trials

View clinical trials related to Epilepsy, Complex Partial.

Filter by:

NCT ID: NCT00319501 Completed - Epilepsy Clinical Trials

Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Start date: January 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of Vanquix for the management of selected, refractory, patients with epilepsy who require intermittent medical intervention provided by caregivers who are not health care professionals, and who are not under the direct supervision of a healthcare professional at the time of administration to control episodes of acute repetitive seizures (ARS).

NCT ID: NCT00143143 Completed - Epilepsies, Partial Clinical Trials

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Start date: September 2001
Phase: Phase 3
Study type: Interventional

The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

NCT ID: NCT00056576 Completed - Clinical trials for Epilepsy, Complex Partial

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.

NCT ID: NCT00001489 Completed - Epilepsy Clinical Trials

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

Start date: October 1994
Phase: N/A
Study type: Observational

This study is designed to test the effects of vigabatrin (gamma-vinyl-GABA) an experimental drug used for the treatment of epilepsy. The study will use positron emission tomography (PET scan) to detect areas of the brain receiving increased blood flow and using increased amounts of glucose. Increases in blood flow and glucose use are good indicators of brain activity. Researchers are interested in determining the effects of Vigabatrin on brain blood flow and glucose use.